



US 20040259923A1

(19) **United States**

(12) **Patent Application Publication**  
**Inoue et al.**

(10) **Pub. No.: US 2004/0259923 A1**

(43) **Pub. Date: Dec. 23, 2004**

(54) **THIAZOLE DERIVATIVES**

**Related U.S. Application Data**

(75) Inventors: **Takayuki Inoue**, Osaka (JP); **Takashi Tojo**, Osaka (JP); **Masataka Morita**, Osaka (JP); **Mitsuru Ohkubo**, Osaka (JP); **Kousei Yoshihara**, Osaka (JP); **Akira Nagashima**, Osaka (JP)

(60) Provisional application No. 60/442,509, filed on Jan. 27, 2003. Provisional application No. 60/458,369, filed on Mar. 31, 2003. Provisional application No. 60/517,377, filed on Nov. 6, 2003.

**Publication Classification**

Correspondence Address:  
**OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.**  
**1940 DUKE STREET**  
**ALEXANDRIA, VA 22314 (US)**

(51) **Int. Cl.<sup>7</sup>** ..... **A61K 31/427**; **A61K 31/426**;  
C07D 417/02  
(52) **U.S. Cl.** ..... **514/370**; **548/181**; **548/190**

(57) **ABSTRACT**

(73) Assignee: **Fujisawa Pharmaceutical Co. Ltd.**,  
Osaka (JP)

(21) Appl. No.: **10/764,529**

(22) Filed: **Jan. 27, 2004**

A compound of the formula (I):  $R^1-NH-X-Y-Z$  (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.